Allstate Corp Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allstate Corp bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 3,798 shares of the biopharmaceutical company’s stock, valued at approximately $894,000.

A number of other institutional investors have also added to or reduced their stakes in ALNY. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock valued at $2,996,296,000 after acquiring an additional 98,303 shares in the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Norges Bank acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $577,941,000. Geode Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.7% in the fourth quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock valued at $377,443,000 after buying an additional 11,291 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,017,271.63. This trade represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.6 %

Shares of Alnylam Pharmaceuticals stock opened at $270.02 on Tuesday. The stock has a market capitalization of $35.13 billion, a P/E ratio of -124.43 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock’s 50-day simple moving average is $260.34 and its 200 day simple moving average is $260.58.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALNY. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $353.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Bank of America raised their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $316.25.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.